Abstract: New high molecular weight salts of hyaluronic acid, especially salts having as a counterion a natural amino acid are described. They are prepared starting from high molecular weight hyaluronic acid or its salts. These high molecular weight salts of hyaluronic acid are advantageously employed in cosmetic and pharmaceutical uses.
Abstract: Aqueous compositions of toremifene or a pharmaceutically acceptable salt thereof, comprising lactic acid, acetic acid, formic acid, methanesulfonic acid or the corresponding anion (lactate, acetate, formate or mesylate) as a solubility enhancing agent. Novel salts of toremifene with an acid selected from the group consisting of lactic acid, acetic acid, formic acid or methanesulfonic acid.
Type:
Grant
Filed:
September 4, 2001
Date of Patent:
December 10, 2002
Assignee:
Orion Corporation
Inventors:
Kaija Af Ursin, Jukka Salmia, Heikki Niskanen, Pirjo Kortesuo, Mikko Kananen, Juha Kiesvaara, Leena Otsomaa
Abstract: Methods, kits, apparatus, and compositions for inhibiting a cerebral neurovascular disorder or a muscular headache in a human patient are provided. The methods comprise intranasally administering to the patient a pharmaceutical composition comprising a local anesthetic, and preferably a long-acting local anesthetic ingredient. A composition useful for practicing the methods of the invention is described which comprises at least one local anesthetic in a pharmaceutically acceptable carrier, wherein the composition is formulated for intranasal delivery. Cerebral neurovascular disorders include migraine and cluster headache. Muscular headaches include tension headaches and muscle contraction headaches. A kit comprising the composition and an intranasal applicator and a method of systemically delivering a pharmaceutically active agent to an animal are also included in the invention.
Abstract: A controlled release composition comprising an adsorbent polymer, an active agent, and a release retardant is disclosed. The composition has an improved ability to release the active agent over an extended time period.
Abstract: Disclosed here are effervescent granules having a controllable rate of effervescence. In some embodiments, the such granules comprise an acidic agent, an alkaline agent, a pharmacologically active agent, hot-melt extrudable binder capable of forming a eutectic mixture with the acidic agent and, optionally, a plasticizer. The effervescent granules are made by a hot-melt extrusion process. The present invention also provides a thermal heat process for preparing a pharmacologically active agent containing effervescent granule. In certain aspects, the granules contain pharmacologically active agents such as narcotics, antidiarrheal agents, antiviral agents, anxiolytic agents, a cholesterol lowering agent, an alpha adrenergic blocking agent, a phenanthrene derivative. By way of example, some of the narcotics that may be included in the granules and in the process of preparing the granules include, by way of example: phenanthrene derivatives (e.g., morphine sulfate), and morphine derivatives (e.g.
Abstract: Antimicrobial/pharmaceutical preparations (e.g., solutions, gels, ointments, creams, sustained release preparations, etc.) which comprise chlorite (e.g., a metal salt of a chlorite) in combination with a peroxy compound (e.g., hydrogen peroxide), and methods for using such preparations for disinfection of articles or surfaces (e.g., contact lenses, counter tops, etc.), antisepsis of skin or other body parts, prevention or deterrence of scar formation and/or treatment and prophylaxis of dermal (i.e., skin or mucous membrane) disorders (e.g., wounds, burns, infections, cold sores, ulcerations, psoriasis, acne, or other scar-forming lesions).
Abstract: The method for promoting hair growth and/or reducing hair loss includes providing a certain agent for reducing hair loss and/or promoting hair growth, applying an effective amount of the agent to hair and scalp, after applying the agent massaging the scalp for one to five minutes and leaving the agent on the hair and the scalp for at least 24 hours. The agent includes a compound of the formulae (I), (II) and/or (III):
or a physiologically compatible salt or salts thereof, as effective ingredient.
Type:
Grant
Filed:
January 31, 2001
Date of Patent:
December 3, 2002
Assignee:
Wella Aktiengesellschaft
Inventors:
Peter Damm, Friedrich Noser, Rainer Schweickert, Hans Heinrich, Eva Reinemund
Abstract: The present invention relates to an antimicrobial wipe effective against Gram positive bacteria, Gram negative bacteria, fungi, yeasts, molds, and viruses comprising a porous or absorbent sheet impregnated with an antimicrobial cleansing composition, wherein the antimicrobial cleansing composition comprises from about 0.001% to about 5.0%, by weight of the antimicrobial cleansing composition, of an antimicrobial active; from about 0.05% to about 10%, by weight of the antimicrobial cleansing composition, of an anionic surfactant; from about 0.1% to about 10%, by weight of the antimicrobial cleansing composition, of a proton donating agent; and from about 3% to about 99.85%, by weight of the antimicrobial cleansing composition, water; wherein the composition is adjusted to a pH of from about 3.0 to about 6.0; wherein the antimicrobial cleansing composition an One-wash Immediate Germ Reduction Index of greater than about 1.
Type:
Grant
Filed:
March 27, 2000
Date of Patent:
December 3, 2002
Assignee:
The Procter & Gamble Company
Inventors:
Peter William Beerse, Jeffrey Michael Morgan, Kathleen Grieshop Baier, Theresa Anne Bakken Schuette, Raymond Wei Cen
Abstract: Plasters containing active substance, comprising a backing material and, applied thereon, a hot-melt self-adhesive composition, characterized in that the hot-melt self-adhesive composition comprises at least one hyper-aemic active substance.
Type:
Grant
Filed:
December 2, 1997
Date of Patent:
December 3, 2002
Assignee:
Beiersdorf AG
Inventors:
Peter Himmelsbach, Helmut Linder, Katharina Broschk, Marike Sinnen, Matthias Wasner
Abstract: The present invention is directed to pyrrolidine compounds of the formula I:
(wherein R1, R2, R3, R4c, R4d, and R4f are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-3 and/or CCR-5.
Type:
Grant
Filed:
March 1, 2000
Date of Patent:
December 3, 2002
Assignee:
Merck & Co., Inc.
Inventors:
Jianming Bao, Robert K. Baker, William H. Parsons, Kathleen Rupprecht
Abstract: A novel microcapsule comprising a liquid core material which is substantially insoluble in water and enclosed within a solid permeable shell of a polymer resin containing disulfide linkages is disclosed. The process for producing such microcapsules is likewise disclosed.
Type:
Grant
Filed:
September 7, 2000
Date of Patent:
November 26, 2002
Assignee:
Syngenta Ltd.
Inventors:
Ian Malcolm Shirley, Juanita Elena Van Koppenhagen, Herbert Benson Scher, Richard Follows, Philip Wade, Fergus Gerard Paul Earley, Dianne Beth Shirley
Abstract: The invention relates to an injectable curable bone cement paste based on bioresorbable hydroxyapatite-like compounds comprising calcium phosphate, which contains a cationic antibiotic in the form of a salt, preferably of its sulfate, the curable biodegradable bone cement releasing the antibiotic in biologically active concentrations with depot-like action over a long period of time. The bone cements according to the invention are suitable for the treatment of infectious inflammations of the bone and of the bone marrow, in particular as a result of bone defects and bone fractures.
Abstract: A formulation for non-invasive delivery of pharmaceutical agents, particularly proteins and peptides, by absorption through a membrane at a targeted site is provided, along with a process of making the formulation. The formulation comprises a suspension of solid-phase dehydrated particles in a delivery medium. The particles comprise the dehydration product of the pharmaceutical agent and at least one of a surfactant and permeation enhancer, and the delivery medium preferably comprises a propellant for pressurized aerosol delivery of the formulation. The formulation can be conveniently delivered to the patient's targeted site where the pharmaceutical agent is absorbed through the mucosa to achieve a desired bioavailability.
Type:
Grant
Filed:
June 2, 2000
Date of Patent:
November 26, 2002
Assignee:
DelRx Pharmaceutical Corp.
Inventors:
Randall McCoy, Miles Augustus Libbey, III, Jle Liu, Robert O. Williams, III
Abstract: This invention provides a feedstock for improving the lactational performance of dairy cows. An essential feature of the feedstock is a dietary cation-anion difference (DCAD) with a value between about 20-60 meq/100 g dietary DM. Other essential features of the feedstock are an atomic ratio of potassium:sodium between about 1-5:1, and a weight ratio of potassium:magnesium between about 3-5:1.
Type:
Grant
Filed:
May 1, 2000
Date of Patent:
November 26, 2002
Assignee:
Church & Dwight Co., Inc.
Inventors:
Elliot Block, William K. Sanchez, Kenneth R. Cummings
Abstract: The invention provides a composition suitable for topical application comprising: an effective amount of a prostaglandin, a polymer thickener, a lipophilic component, and a buffer system. In another embodiment, the invention provides a composition suitable for topical application comprising: an effective amount of a vasoactive agent, a polymer thickener, a lipophilic component, and a buffer system. The invention also provides methods of ameliorating female sexual dysfunction. Also provided are methods of increasing female sexual arousal and methods of enhancing female sexual response.
Type:
Grant
Filed:
December 10, 1998
Date of Patent:
November 26, 2002
Assignee:
NexMed (Holdings), Inc.
Inventors:
James L. Yeager, Nadir Buyuktimkin, Servet Buyuktimkin
Abstract: The present invention provides methods for preventing, treating, and/or managing one or more cancerous conditions in a patient, such as a human. A multivalent metal oxide, such as Ag(I,III), Cu(I,III), Pr(III,IV), and Bi(III,V) oxides or a pharmaceutically acceptable derivative thereof, may be administered to the patient in an amount and for a period of time which is therapeutically effective to prevent, treat, and/or manage such condition(s). These cancerous conditions include systemic and external cancers, and may also include conditions and symptoms associated with cancer. The present invention also provides a pharmaceutical composition suitable for treating such cancerous conditions. The compositions of the invention may be adapted for at least one of subcutaneous injection, intramuscular injection, intravenous injection, infusion, transdermal, or topical application.
Abstract: A method and apparatus is disclosed for treating asthma and other respiratory conditions. A medicament comprising a surface active phospholipid (SAPL) is prepared in the form of a fine powder and administered to the lungs in a gas stream. A preferred SAPL is a solid blend of dipalmitoyl phosphatidyl choline (DPPC) and phosphatidyl glycerol (PG).
Type:
Grant
Filed:
August 10, 2000
Date of Patent:
November 19, 2002
Assignee:
Britannia Pharmaceuticals Limited
Inventors:
Brain Andrew Hills, Derek Alan Woodcock
Abstract: Novel, stable pharmaceutical formulations for the oral administration of high purity torsemide modification II are disclosed. These formulations release high purity torsemide modification II in water at a constant and high purity rate, and the high purity torsemide modification II therein does not rearrange to torsemide modification I over time. Methods for their manufacture are also disclosed.
Type:
Grant
Filed:
February 21, 2001
Date of Patent:
November 19, 2002
Assignee:
Teva Pharmaceutical Industries Ltd.
Inventors:
Minutza Leibovici, Ruth Tenengauzer, Mira Kopel, Judith Aronhime, Marco Kordova
Abstract: A composition having a bactericidal action is provided which has no toxicity to the human body, and particularly a composition having a bactericidal action is provided which exhibit an excellent therapeutic effect for skin diseases such as atopic dermatitis, acne or the like.
A composition, in which an extract from a silk gland and/or a liquid silk is an active ingredient, has a bactericidal action to make renewal of a skin cell, exhibiting an excellent therapeutic effect for skin diseases.